These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
986 related articles for article (PubMed ID: 27376363)
1. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Akhtar S; Rauf SM; Elhassan TA; Maghfoor I Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363 [TBL] [Abstract][Full Text] [Related]
2. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant. Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748 [TBL] [Abstract][Full Text] [Related]
3. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455 [TBL] [Abstract][Full Text] [Related]
4. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108 [TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Rauf MS; Maghfoor I; Elhassan TA; Akhtar S Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839 [TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917 [TBL] [Abstract][Full Text] [Related]
7. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837 [TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949 [TBL] [Abstract][Full Text] [Related]
9. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168 [TBL] [Abstract][Full Text] [Related]
10. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290 [TBL] [Abstract][Full Text] [Related]
11. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660 [TBL] [Abstract][Full Text] [Related]
12. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139 [TBL] [Abstract][Full Text] [Related]
15. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652 [TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893 [TBL] [Abstract][Full Text] [Related]
17. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692 [TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
19. High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm. Akhtar S Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):272-276. PubMed ID: 28641095 [TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J; Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]